All In Biotech

Free tool

FAERS Monitor: Jakafi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202192 or its brand name (Jakafi, Ruxolitinib Phosphate). Reports on generic versions are filed under their own applications.

Reports

68,626

Serious

34,968

51% of reports

Hospitalization

13,793

Death reported

9,975

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use14,354
  • death6,468
  • fatigue6,200
  • anaemia3,160
  • haemoglobin decreased2,999
  • platelet count decreased2,726
  • diarrhoea2,709
  • asthenia2,567
  • dizziness2,518
  • product dose omission issue2,480
  • headache2,393
  • pneumonia2,193
  • nausea2,171
  • product availability issue2,022
  • weight increased2,000

Reports by year received

View as table
YearReports
2012483
2013839
20142,779
20152,509
20164,603
20174,335
20185,006
20195,210
20206,094
20216,475
20226,434
20236,566
20246,205
20256,136
20264,952

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,985,533 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product availability issueSignal2,02229.828.551,260
haemoglobin decreasedSignal2,9999.28.921,348
platelet count decreasedSignal2,7268.07.716,393
anaemiaSignal3,1605.15.010,474
off label useSignal14,3545.15.048,429
weight increasedSignal2,0002.82.62,234
product dose omission issueSignal2,4802.62.52,450
fatigueSignal6,2002.52.45,492
deathSignal6,4682.32.34,976
astheniaSignal2,5672.12.01,494
pneumoniaSignal2,1932.12.01,245
dizziness2,5181.61.5500
diarrhoea2,7091.31.2178
headache2,3931.21.161
nausea2,1710.80.868

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.